Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Teratogenicity

Teratogenicity

The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

In-depth characterization of a new patient-derived xenograft model for metaplastic breast carcinoma to identify viable biologic targets and patterns of matrix evolution within rare tumor types.

Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·2021

Same author

Racial differences in intracerebral haemorrhage outcomes in patients with obesity.

Obesity science & practice·2018

Same author

Activation of aryl hydrocarbon receptor regulates the LPS/IFNγ-induced inflammatory response by inducing ubiquitin-proteosomal and lysosomal degradation of RelA/p65.

Biochemical pharmacology·2018

Same author

Electrical transport measurements of thin film samples under high hydrostatic pressure.

The Review of scientific instruments·2017

Same author

Comparative transcriptomic analysis reveals the oncogenic fusion protein PAX3-FOXO1 globally alters mRNA and miRNA to enhance myoblast invasion.

Oncogenesis·2016

Same author

Norovirus as the cause of medically attended gastroenteritis: a hospital-based experience.

Epidemiology and infection·2016

Search research articles

Related Experiment Video

Updated: Jul 7, 2026

Isolation of Leukocytes from the Murine Tissues at the Maternal-Fetal Interface

Isolation of Leukocytes from the Murine Tissues at the Maternal-Fetal Interface

Published on: May 21, 2015

[Etanercept and pregnancy].

I Otermin¹, G Elizondo, J Zabaleta

¹Servicio de Medicina Interna, Clínica Ubarmin, Elcano, Navarra, Spain. inaki.otermin.maya@cfnavarra.es

Anales Del Sistema Sanitario De Navarra

|January 30, 2008

Summary

This summary is machine-generated.

This case study shows that continuing etanercept treatment during pregnancy for arthritis is safe. The patient received standard doses without any adverse effects, indicating potential safety for pregnant individuals with arthritis.

Related Experiment Videos

Last Updated: Jul 7, 2026

Isolation of Leukocytes from the Murine Tissues at the Maternal-Fetal Interface

Isolation of Leukocytes from the Murine Tissues at the Maternal-Fetal Interface

Published on: May 21, 2015

Area of Science:

Rheumatology
Immunology
Obstetrics

Background:

Rheumatoid arthritis and other inflammatory arthropathies can affect women of childbearing age.
Treatment decisions for arthritis during pregnancy require careful consideration of maternal and fetal safety.
Etanercept is a biologic disease-modifying antirheumatic drug (DMARD) used for various inflammatory conditions.

Observation:

A pregnant woman with arthritis was undergoing treatment with etanercept.
She continued receiving etanercept at a standard dose of 25 mg twice weekly throughout her pregnancy.
The pregnancy and fetal development proceeded without any reported complications.

Findings:

Continued treatment with etanercept during pregnancy was associated with no adverse outcomes in this case.
Standard dosing of etanercept (25 mg twice weekly) was maintained without complications.
This suggests etanercept may be a viable treatment option for certain pregnant patients with arthritis.

Implications:

This case provides preliminary evidence supporting the safety of etanercept use in pregnancy for managing arthritis.
Further research, including larger studies, is warranted to confirm the safety and efficacy of etanercept in pregnant populations.
Clinicians may consider etanercept for pregnant patients with arthritis when benefits outweigh potential risks, pending further data.